


REMARKS

Support for the amendments is found throughout the specification as originally filed. For example, support for the amendment of claims 1, 6, 85, 96, 107, and their dependent claims, which recite "lacks pore-forming ability" is found at page 3, lines 14 and 15, and at page 12, lines 12-20; support for the amendment of claims 1 and 6 and new claims 65-117, which recite specific mutations, is found throughout the claims as originally filed, in Table 1, and at page 4, lines 15-17; support for new claims 85-117, which recite fusion polypeptides is found at page 4, lines 13-15; support for the amendment of claims 1 and 6 and new claims 65-117, which recite "provokes an immune response when injected into a subject," "immunogenic composition," or "methods of inducing an immune response," is found, for example, at page 4, lines 23-25, and at pages 39-42. No new matter has been added by the present amendment.


If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 5/19/04


Kristina Bieker-Brady, Ph.D., P.C.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045


Michael J. Belliver, Ph.D.
Reg. No. 52,608